gtcb - I talked to gtcb today. I asked if about the bioinvestor conf call pointing toward a particular company having a interest in partnering with GTCB. The person I talked to did confirm that information. No company name given.
I also asked about the additional EMEA delay time to Feb. For the most part our conversation was nothing new. One thing that was mentioned is that the EMEA is graded on turnover time for new drug applications. I just thought this was important as far as the EMEA just delaying and delaying for no given reason other then to not wanting to approve a transgenic drug. I still would not rule this out but if I was being graded on turnover time, and I didn't want to approve a drug I would just tell the company it's not going to happen and be done with it.
Market Data 
Markets 
AI
